Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07236099 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
A Phase 2 study, sponsored by Beijing InnoCare Pharma Tech Co..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
NCT07236099: Recruiting Phase 2 study, sponsored by Beijing InnoCare Pharma Tech Co..
NCT07236099 is a Phase 2 study that is actively recruiting participants, run by Beijing InnoCare Pharma Tech Co.. The registered enrollment target is 135 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07236099, a Phase 2 study, is actively recruiting participants, sponsored by Beijing InnoCare Pharma Tech Co..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
Study Summary
Evaluate the efficacy and safety of ICP-332 in participants with Prurigo Nodularis (PN)
Primary Outcome
Percent change from baseline of weekly average in Peak pruritus-numeric rate scale (PP NRS) at Week 16. Participants will be asked to rate their itch at the worst moment during the previous 24 hours. On a scale of 0 to 10, with 0 being 'no itch' and 10 being the 'worst itch imaginable'.
Interventions
- DRUG Placebo
- DRUG ICP-322
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2025-11-27 |
| Est. Completion | 2027-10 |
| Phase | Phase 2 |
What NCT07236099 shows while recruiting
NCT07236099 is an interventional study that assigns participants to a tested intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07236099 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07236099 about?
NCT07236099 is a clinical study titled "Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis". Evaluate the efficacy and safety of ICP-332 in participants with Prurigo Nodularis (PN)
What is the current status of trial NCT07236099?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2025-11-27. Estimated completion is 2027-10.
What interventions are being tested in trial NCT07236099?
The interventions under investigation include: Placebo (DRUG), ICP-322 (DRUG).
Who is sponsoring clinical trial NCT07236099?
This trial is sponsored by Beijing InnoCare Pharma Tech Co., which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07236099's enrollment target sits among peer trials
135 532nd of 2000 higher than 1,464 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI